Special section: Food allergyWorld Allergy Organization anaphylaxis guidelines: Summary
Section snippets
Assessment of patients with anaphylaxis
The World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis alert health care professionals to patient factors that increase the risk of severe or fatal anaphylaxis. These include very young and very old age, concomitant diseases such as asthma, cardiovascular diseases, and mastocytosis or clonal mast cell disorders, and concurrent medications such as β-adrenergic blockers and angiotensin-converting enzyme inhibitors. Psychiatric illness (eg, depression), and use
Management of anaphylaxis in a health care setting
The WAO Guidelines for the Assessment and Management of Anaphylaxis focus on a systematic approach to the basic initial assessment and management of anaphylaxis, emphasizing the primary role of epinephrine (adrenaline) in treatment. The recommendations that are made are relatively inexpensive to implement and should be possible even in a low-resource environment, as previously described (Fig 4). A critically important philosophy expressed throughout is that if precious minutes are lost early in
Management of anaphylaxis at the time of discharge from a health care setting
The World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis emphasize the important role of the allergy/immunology specialist in the long-term management of patients who are at risk for recurrence of anaphylaxis in the community. At the time of discharge from a health care setting, such patients should be equipped with epinephrine for self-administration, a written personalized anaphylaxis emergency action plan stating the common symptoms and signs of anaphylaxis,
Summary
The World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis are being published concurrently in the Journal of Allergy and Clinical Immunology to facilitate retrieval by all health care professionals worldwide through PubMed and other search engines and in the World Allergy Organization Journal to facilitate rapid access by all members of the WAO. The recommendations for assessment and basic initial management of anaphylaxis, as summarized in Fig 1, Fig 2, Fig 3,
References (0)
Cited by (469)
Neuromuscular blocking agent re-exposure in a retrospective cohort with neuromuscular blocking agent–associated anaphylaxis
2023, Annals of Allergy, Asthma and ImmunologyContextual community epinephrine prescribing: Is more always better?
2023, Annals of Allergy, Asthma and ImmunologyKnowledge gaps in the diagnosis and management of anaphylaxis
2023, Annals of Allergy, Asthma and ImmunologyPrehospital epinephrine administration for treating anaphylaxis among those with comorbid asthma: A scoping review
2023, Annals of Allergy, Asthma and ImmunologyPenicillin Allergy: Mechanisms, Diagnosis, and Management
2023, Primary Care - Clinics in Office Practice
Disclosure of potential conflict of interest: F. E. R. Simons has received research support from the Canadian Institutes of Health Research and is on the Anaphylaxis Advisory Boards for Dey, Sanofi-Aventis, and ALK-Abelló. M. B. Bilò has given lectures for ALK-Abelló and Phadia. D. K. Ledford has received research support from Forest Labs, Genentech/Abbott, Merck, and Viro Dharma. A. Sheikh is a Clinical Champion for the Royal College of General Practitioners and a consultant for ALK-Abelló, has done advisory work for Phadia, and is an advisor for the Royal College of Pediatrics and Child Health. The rest of the authors have declared that they have no conflict of interest.
The “World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis” was originally published as a WAO position paper in: Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford DK, et al. World Allergy Organization Journal 2011;2(3):13-36 on February 24, 2011.